A recombinant adenovirus-based vector elicits a specific humoral immune response against the V3 loop of HIV-1 gp120 in mice through the “Antigen Capsid-Incorporation” strategy

BACKGROUND: Due to potential advantages, human adenoviral vectors have been evaluated pre-clinically as recombinant vaccine vectors against several cancers and infectious diseases, including human immunodeficiency virus (HIV) infection. The V3 loop of HIV-1 glycoprotein 120 (gp120) contains importan...

Descripción completa

Detalles Bibliográficos
Autores principales: Gu, Linlin, Krendelchtchikova, Valentina, Krendelchtchikov, Alexandre, Oster, Robert A, Fujihashi, Kohtaro, Matthews, Qiana L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4065546/
https://www.ncbi.nlm.nih.gov/pubmed/24935650
http://dx.doi.org/10.1186/1743-422X-11-112

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4065546/
https://www.ncbi.nlm.nih.gov/pubmed/24935650
http://dx.doi.org/10.1186/1743-422X-11-112

Ejemplares similares